Osiris Therapeutics Inc (OSIR.OQ)

OSIR.OQ

About

Osiris Therapeutics, Inc. (Osiris) is a stem cell therapeutic company. It focuses on developing and marketing products to treat serious medical conditions in the inflammatory, autoimmune, orthopedic and cardiovascular areas. The Company’s biologic drug candidate, Prochymal, is being evaluated in Phase III clinical trials for... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	0.35
Market Cap (Mil.):	$454.35
Shares Outstanding (Mil.):	32.85
Dividend:	--
Yield (%):	--

Financials

	OSIR.OQ	Industry	Sector
P/E (TTM):	47.86	16.62	43.38
EPS (TTM):	0.29	--	--
ROI:	24.60	5.53	9.53
ROE:	24.88	8.36	11.11

Latest News about OSIR.OQ

» More OSIR.OQ News

Competitors

	Price	Change
Johnson & Johnson (JNJ.N)	$66.84	+0.42
Abbott Laboratories (ABT.N)	$62.87	+0.52
Biogen Idec Inc. (BIIB.OQ)	$143.16	+1.19
Biogen Idec Inc. (68246039)	--	--
Aastrom Biosciences, Inc. (ASTM.OQ)	$2.18	+0.01
Advanced Cell Technology, Inc. (ACTC.OB)	$0.06	+0.00
Athersys, Inc. (ATHX.OQ)	$1.55	+0.08
Cytori Therapeutics Inc. (USA) (CYTX.OQ)	$2.64	-0.02
Geron Corporation (GERN.OQ)	$1.76	+0.14
Mesoblast limited (MSB.AX)	$5.92	+0.18

Earnings vs Estimates

Analyst Research Reports

Report Title	Price
OSIR - Osiris Therapeutics Inc - FullReport Provider: Alpha Street Research	$16.00 Buy
OSIRIS THERAPEUTICS INC (OSIR) - REPORT FOR ACTIVE TRADERS Provider: Pechala's Reports	$25.00 Buy
Thomson Reuters Stock Report - OSIRIS THERAPEUTICS, INC. (OSIR-O) Provider: Thomson Reuters Stock Report	$25.00 Buy
ValuEngine Detailed Valuation Report for OSIR Provider: ValuEngine, Inc.	$127.00 Buy
Osiris Therapeutics Provider: Standard & Poor's Quantitative Report	$69.00 Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Related Topics:

Edition:

U.S.
- Africa
- Arabic
- Argentina
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Latin America
- Mexico
- Russia
- Spain
- United Kingdom

Back to top

Reuters.com

Legal

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.